BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 36287298)

  • 21. [Effect of the tetra-arsenic tetra-sulfide (As4S4) on the corrected QT interval in the treatment of acute promyelocytic leukemia].
    Shen JC; Liu KY; Jiang B; Lu XJ; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2004 Jun; 25(6):359-61. PubMed ID: 15308017
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative proteome study of apoptosis induced by As4S4 in retinoid acid resistant human acute promyelocytic leukemia NB4-R1 cells.
    Qi J; He P; Chen W; Wang H; Wang X; Zhang M
    Leuk Res; 2010 Nov; 34(11):1506-16. PubMed ID: 20403635
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Mechanism of tetra-arsenic tetra-sulfide in inducing apoptosis of acute promyelocytic leukemia cells].
    Teng ZP; Zhang P; Zhu HH; Hao HY; Qin XY; Hao L; Xu H; Lu DP
    Beijing Da Xue Xue Bao Yi Xue Ban; 2006 Jun; 38(3):236-8. PubMed ID: 16778962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies.
    Chen Z; Chen GQ; Shen ZX; Chen SJ; Wang ZY
    Semin Hematol; 2001 Jan; 38(1):26-36. PubMed ID: 11172537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retinoic acid syndrome induced by arsenic trioxide in treating recurrent all-trans retinoic acid resistant acute promyelocytic leukemia.
    Che-Pin Lin ; Huang MJ; Chang IY; Lin WY; Sheu YT
    Leuk Lymphoma; 2000 Jun; 38(1-2):195-8. PubMed ID: 10811463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide: review of clinical and basic studies.
    Liu P; Han ZC
    Int J Hematol; 2003 Jul; 78(1):32-9. PubMed ID: 12894848
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful treatment of all-trans retinoic acid resistant and chemotherapy naïve acute promyelocytic patients with arsenic trioxide--two case reports.
    Lin CP; Huang MJ; Chang IY; Lin WY
    Leuk Lymphoma; 2000 Jun; 38(1-2):191-4. PubMed ID: 10811462
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The impact of arsenic trioxide or all-trans retinoic acid treatment on coagulopathy in acute promyelocytic leukemia].
    Zhang X; Zhou H; Song S; Qiao Z; Yang L; Hu Y
    Zhonghua Nei Ke Za Zhi; 2001 Dec; 40(12):829-33. PubMed ID: 16206674
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid.
    Kitamura K; Hoshi S; Koike M; Kiyoi H; Saito H; Naoe T
    Br J Haematol; 2000 Mar; 108(4):696-702. PubMed ID: 10792271
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic evaluation of arsenic trioxide compared to all-trans retinoic acid + conventional chemotherapy for treatment of relapsed acute promyelocytic leukemia in Canada.
    Lachaine J; Mathurin K; Barakat S; Couban S
    Eur J Haematol; 2015 Sep; 95(3):218-29. PubMed ID: 25354894
    [TBL] [Abstract][Full Text] [Related]  

  • 31. All-Trans Retinoic Acid plus Arsenic Trioxide versus All-Trans Retinoic Acid plus Chemotherapy for Newly Diagnosed Acute Promyelocytic Leukemia: A Meta-Analysis.
    Ma Y; Liu L; Jin J; Lou Y
    PLoS One; 2016; 11(7):e0158760. PubMed ID: 27391027
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distinct TP73-DAPK2-ATG5 pathway involvement in ATO-mediated cell death versus ATRA-mediated autophagy responses in APL.
    Humbert M; Federzoni EA; Tschan MP
    J Leukoc Biol; 2017 Dec; 102(6):1357-1370. PubMed ID: 28978663
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome.
    Luesink M; Pennings JL; Wissink WM; Linssen PC; Muus P; Pfundt R; de Witte TJ; van der Reijden BA; Jansen JH
    Blood; 2009 Dec; 114(27):5512-21. PubMed ID: 19828696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells.
    Takeshita A; Shinjo K; Naito K; Matsui H; Sahara N; Shigeno K; Horii T; Shirai N; Maekawa M; Ohnishi K; Naoe T; Ohno R
    Leukemia; 2005 Aug; 19(8):1306-11. PubMed ID: 15920495
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide.
    Shepshelovich D; Oniashvili N; Parnes D; Klein A; Muchtar E; Yeshaya J; Aviram A; Rabizadeh E; Raanani P
    Cancer Genet; 2015 Nov; 208(11):575-9. PubMed ID: 26471811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of all-trans retinoic acid and arsenic trioxide on tissue factor expression in acute promyelocytic leukemia cells.
    Guo W; Wang H; Zhao W; Zhu J; Ju B; Wang X
    Chin Med J (Engl); 2001 Jan; 114(1):30-4. PubMed ID: 11779431
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Comparison of efficacy and adverse effects between arsenic trioxide and all-trans retinoic acid in patients with acute promyelocytic leukemia].
    Jiao L; Wang SJ; Zhuang JL; Zhao YQ; Zhou DB; Xu Y; Han B; Zhang W; Duan MH; Zou N; Zhu TN; Shen T
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct; 31(5):555-8. PubMed ID: 19968069
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia.
    Hu J; Liu YF; Wu CF; Xu F; Shen ZX; Zhu YM; Li JM; Tang W; Zhao WL; Wu W; Sun HP; Chen QS; Chen B; Zhou GB; Zelent A; Waxman S; Wang ZY; Chen SJ; Chen Z
    Proc Natl Acad Sci U S A; 2009 Mar; 106(9):3342-7. PubMed ID: 19225113
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia.
    Cai X; Shen YL; Zhu Q; Jia PM; Yu Y; Zhou L; Huang Y; Zhang JW; Xiong SM; Chen SJ; Wang ZY; Chen Z; Chen GQ
    Leukemia; 2000 Feb; 14(2):262-70. PubMed ID: 10673743
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Retinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cells.
    Valenzuela M; Glorieux C; Stockis J; Sid B; Sandoval JM; Felipe KB; Kviecinski MR; Verrax J; Buc Calderon P
    Br J Cancer; 2014 Aug; 111(5):874-82. PubMed ID: 25003661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.